期刊文献+

Integrated DNA-based/biochemical screening for early diagnosis of multiple endocrine neoplasia type 2A (MEN2A) 被引量:3

Integrated DNA-based/biochemical screening for early diagnosis of multiple endocrine neoplasia type 2A (MEN2A)
下载PDF
导出
摘要 Multiple endocrine neoplasia type 2A (MEN2A), a subtype of MEN2, is characterized by medullary thyroid cancer, pheochromocytoma, and primary hyperparathyroidism. A Han Chinese pedigree with MEN2A was investigated following confirmation of the proband's diagnosis by pathological findings and DNA/biochemical screening. DNA samples from 4 other family members were collected and exon 5, 8, 10, 11, 13, 16 and 18 of the RET proto-oncogene were sequenced and then analyzed. A missense mutation of TGG (Trp) to TGC (Cys) at codon 634 (the classic MEN2A mutation) in exon 11 of the RET gene was detected in 3 family members, including the proband. Sequencing data were compared with the human gene mutation database. Elevated serum calcitonin level was detected initially; medullary thyroid carcinoma was revealed in the 3 cases and adrenal pheochromocytoma was also found in the proband. Elective operations were successfully performed on the adrenal and thyroid glands because of pheochromocytoma and medullary thyroid carcinoma. Our case study confirms that integrated DNA-based/biochemical screening is crucial for early diagnosis of MEN2A and is helpful in the screening of their relatives. In addition, DNA-based screening may occasionally uncover a previously unknown RET sequence. Multiple endocrine neoplasia type 2A (MEN2A), a subtype of MEN2, is characterized by medullary thyroid cancer, pheochromocytoma, and primary hyperparathyroidism. A Han Chinese pedigree with MEN2A was investigated following confirmation of the proband's diagnosis by pathological findings and DNA/biochemical screening. DNA samples from 4 other family members were collected and exon 5, 8, 10, 11, 13, 16 and 18 of the RET proto-oncogene were sequenced and then analyzed. A missense mutation of TGG (Trp) to TGC (Cys) at codon 634 (the classic MEN2A mutation) in exon 11 of the RET gene was detected in 3 family members, including the proband. Sequencing data were compared with the human gene mutation database. Elevated serum calcitonin level was detected initially; medullary thyroid carcinoma was revealed in the 3 cases and adrenal pheochromocytoma was also found in the proband. Elective operations were successfully performed on the adrenal and thyroid glands because of pheochromocytoma and medullary thyroid carcinoma. Our case study confirms that integrated DNA-based/biochemical screening is crucial for early diagnosis of MEN2A and is helpful in the screening of their relatives. In addition, DNA-based screening may occasionally uncover a previously unknown RET sequence.
出处 《The Journal of Biomedical Research》 CAS 2013年第2期145-150,共6页 生物医学研究杂志(英文版)
基金 supported by grant 81170747 from the National Natural Sciences Foundation of China grant H201106 from Health Promotion Foundation of Jiangsu Province grant from the Office of Human Resources and Social Security of Jiangsu Province (Peak of the Six Personnel in Jiangsu Province) to Hongwen Zhou
关键词 MEN-2A RET mutation medullary thyroid carcinoma Chinese RET proto-oncogene Calcitoninscreening DNA-based screening MEN-2A, RET mutation, medullary thyroid carcinoma, Chinese, RET proto-oncogene, Calcitoninscreening, DNA-based screening
  • 相关文献

参考文献18

  • 1Brandi ML, Gagel RF, Angell A, Bilezikian JP, Beck- Peccoz P, Bordi C, et al. Guidelines for diagnosis and therapy of MEN type 1 and type 2. J. Clin. Endocrinol Metab 2001; 86: 5658-71.
  • 2Steiner AL, Goodman AD, Powers SR. Study of a kin- dred with pheochromocytoma, medullary thyroid carci- noma, hyperparathyroidism and Cushing's disease: mul- tiple endocrine neoplasia, type 2. Medicine (Baltimore) 1968; 47: 371-409.
  • 3Traugott AL, Moley JF. Multiple endocrine neoplasia type 2: clinical manifestations and management. Cancer Treat Res 2010; 153: 321-37.
  • 4Machens A, Lorenz K, Dralle H. Individualization of lymph nodedissection in RET (rearranged during trans- fection) carriers at risk for medullary thyroid cancer: value of pretherapeutic calcitonin levels. Ann Surg. 2009; 250: 305-10.
  • 5Howe JR, Norton JA, Wells Jr. SA. Prevalence of pheo- chromocytorna and hyperparathyroidism in multiple en- docrine neoplasia type 2A: results of long-term follow- up. Surgery 1993; 114: 1070-7.
  • 6Sawka AM, Jaeschke R, Singh RJ, Young WF Jr. A comparison of biochemical tests for phechromocytoma: measurement of fractionated plasma metanephrines compared with the combination of 24-hour urinary me- tanephrines and catecholamines. J Clin Endocrinol Me- tab 2003; 88: 553-8.
  • 7Mulligan LM, Marsh DJ, Robinson BG, Schuffenecker I, Zedenius J, Lips C J, et al. Genotype-phenotype correla- tion in multiple endocrine neoplasia type 2: report of the International RET Mutation Consortium. J Intern Med 1995; 238: 343-6.
  • 8Eng C, Clayton D, Schuffenecker I, Lenoir G, Cote G, Gagel RF, et al. The relationship between specific RET proto-oncogene mutation and disease phenotype in mul- tiple endocrine neoplasia type 2: International RET mu- tation consortium analysis. JAMA 1996; 276: 1575-9.
  • 9Kloos RT, Eng C, Evans DB, Francis GL, Gagel RF, Gharib H, et al. Medullary thyroid cancer: management guidelines of the American Thyroid Association. Thy- roid 2009; 19: 565-612.
  • 10Moley JF. The molecular genetics of multiple endocrine neoplasia type 2A and related syndromes. Annu Rev Med 1997; 48: 409-20.

同被引文献14

引证文献3

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部